The U.S. companion diagnostics (CDx) development market was valued at USD 412.84 million in 2024, with a projected compound annual growth rate (CAGR) of 7.8% expected from 2025 to 2034. This growth is being shaped by a complex interplay of regulatory frameworks, technological advancements, and evolving healthcare paradigms across key global regions. North America remains the dominant region for...